GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,750.00p
   
  • Change Today:
      14.50p
  • 52 Week High: 2,208.00p
  • 52 Week Low: 1,620.00p
  • Currency: UK Pounds
  • Shares Issued: 4,045.43m
  • Volume: 6,854,112
  • Market Cap: £70,795m
  • RiskGrade: 129
  • Beta: 0.00

Financial Analysis

Select chart: EPS | Dividend | Revenue

Latest Interim/Quarterly

Period Ending Period Revenue (£m) Pre-tax (£m) EPS Dividend
30-Jun-26 Interim 16,038.00 2,498.00 54.10p 34.00p

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%
31-Dec-25 32,667.00 7,401.00 172.00p 10.6 1.3 +8% 66.00p 3.6%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 33,927.49 9,508.54 178.90p 9.8 2.4 +4% 71.13p 0.0%
31-Dec-27 35,489.27 10,576.93 190.25p 9.2 1.4 +6% 76.76p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 22.18 8.45 12.18 0.94

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

GSK Market Data

Currency UK Pounds
Share Price 1,750.00p
Change Today 14.50p
% Change 0.84 %
52 Week High 2,208.00p
52 Week Low 1,620.00p
Volume 6,854,112
Shares Issued 4,045.43m
Market Cap £70,795m
Beta 0.00
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
76.23% below the market average76.23% below the market average76.23% below the market average76.23% below the market average76.23% below the market average
36.84% below the sector average36.84% below the sector average36.84% below the sector average36.84% below the sector average36.84% below the sector average
Price Trend
75.14% above the market average75.14% above the market average75.14% above the market average75.14% above the market average75.14% above the market average
72.09% above the sector average72.09% above the sector average72.09% above the sector average72.09% above the sector average72.09% above the sector average
Income
23.24% above the market average23.24% above the market average23.24% above the market average23.24% above the market average23.24% above the market average
Sector averageSector averageSector averageSector averageSector average
Growth
39.83% above the market average39.83% above the market average39.83% above the market average39.83% above the market average39.83% above the market average
28.57% below the sector average28.57% below the sector average28.57% below the sector average28.57% below the sector average28.57% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 12
Sell 2
Strong Sell 0
Total 21
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q2 Q1
Ex-Div 13-Aug-26 14-May-26
Paid 08-Oct-26 09-Jul-26
Amount 17.00p 17.00p

Trades for 09-Oct-2026

Time Volume / Share Price
17:03 301,000 @ 1,752.00p
16:58 301,000 @ 1,752.00p
16:39 514 @ 1,750.00p
16:39 110 @ 1,750.00p
16:39 4 @ 1,750.00p

GSK Key Personnel

CEO Luke Miels

Top of Page